Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
natural killer cells
Biotech
Artiva plans IPO to fund NK cell therapy's autoimmune trials
The company said the top priority for spending the proceeds will be on continuing the clinical development of its lead program AlloNK.
James Waldron
Jul 1, 2024 7:48am
Synthekine hopes new IL-2 will be the high-alpha in a beta class
Apr 10, 2024 9:50am
Nkarta's blood cancer CAR stalls again, driving deprioritization
Mar 22, 2024 9:11am
Allogene parks Notch CARs, leaving one on the road
Jan 31, 2024 10:35am
Nkarta's cell therapy needs specific preconditioning
Jun 27, 2023 11:02am
Takeda puts $510M on the line to expand KSQ cancer collaboration
May 17, 2023 9:35am
